Other Clinical Trial - Efficacy & Safety of Patupilone in Men (≥18 Years)

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The objective of this study is to assess the response of patupilone plus prednisone compared to docetaxel plus prednisone on prostate specific antigen (PSA) in patients with metastatic hormone refractory prostate cancer. Additionally, this study will assess the response on measureable disease and the effects on patient-reported outcomes.

See also
Status	Clinical Trial	Phase
Completed	`NCT00766324` - PHA-739358 for Treatment of Hormone Refractory Prostate Cancer	Phase 2
Completed	`NCT00636090` - Molecular, Genetic, and Genomic Assessments From Patients Treated With RAD001	N/A
Active, not recruiting	`NCT04477512` - Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)	Phase 1

NCT number	NCT00411528
Study type	Interventional
Source	Novartis
Contact
Status	Completed
Phase	Phase 2
Start date	September 2006
Completion date	September 2012

Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms